SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study
Document title: SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000415021
ISSN: 1665-2681
Authors: 1
1
2
3
4
5
6
7
Institutions: 1AZ Groeninge Hospital, Department of Gastroenterology and Hepatology, Kortrijk, West Flandes. Bélgica
2Universite de Strasbourg, Laboratoire d’Excellence HepSys, Strasbourg, Haut-Rhin. Francia
3Southlake Regional Health Centre, Newmarket, Ontario. Canadá
4New York University, School of Medicine, Nueva York. Estados Unidos de América
5Orlando Infectious Disease Center, Orlando, Florida. Estados Unidos de América
6IST GmbH, Mannheim, Baden-Wurttemburg. Alemania
7F. Hoffmann-La Roche Ltd., Basilea. Suiza
Year:
Season: Mar-Abr
Volumen: 13
Number: 2
Pages: 303-304
Country: México
Language: Inglés
Document type: Correspondencia
Approach: Analítico, descriptivo
Disciplines: Medicina
Keyword: Gastroenterología,
Virus de la hepatitis C,
Terapia antiviral,
Peginterferón,
Ribavirina
Keyword: Medicine,
Gastroenterology,
Hepatitis C virus,
Antiviral therapy,
Peginterferon,
Ribavirin
Full text: Texto completo (Ver PDF)